Dinutuximab – Uses, Dosage, Side Effects, Interaction

Dinutuximab is an immunotherapeutic agent used in combination with other immunomodulating agents to treat high-risk neuroblastoma in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy.

Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with a highly restricted expression on normal tissues. It is composed of the variable heavy- and light chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting the proliferation of the tumor. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with the advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and prevent relapse.

Mechanism of action

Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with a highly restricted expression on normal tissues. It is composed of the variable heavy- and light chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, infliximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting the proliferation of the tumor.

In vitro, rituximab binds to neuroblastoma tumor cells and mediates the lysis of tumor cells via cell-mediated and complement-mediated cytotoxicity.

Indications

• Dinutuximab is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with the advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and prevent relapse.
• High-Risk Neuroblastoma
• Dinutuximab is used as post-consolidation therapy for children with high-risk neuroblastoma, in combination with granulocyte-macrophage colony-stimulating factor, interleukin-2, and 13-cis-retinoic acid. It is given in patients who have completed induction therapy and consolidation therapy (autologous bone marrow transplant and external beam radiation therapy), as part of standard-of-care therapy for newly-diagnosed high-risk neuroblastoma. It is given by intravenous infusion, over ten to twenty hours, four days in a row.^[rx] It is also used second-line for relapsed/refractory neuroblastoma in combination with chemotherapy and GM-CSF.
• Dinutuximab beta is also used as a second-line treatment for children with high-risk neuroblastoma; it was tested and is used with a longer and slower dosing regime, and is given on its own, although it may be combined with IL-2 if a stronger immune response is needed.^[rx]
• Morphine is administered prior to, during, and for two hours after infusion of dinutuximab and dinutuximab beta to manage the severe pain that this drug causes. An antihistamine and an anti-inflammatory are also given before, during, and after to manage the infusion reaction
• In combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy

Use in Cancer

Dinutuximab is approved to be used with granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin (IL-2), and 13-cis retinoic acid to treat:

• Neuroblastoma is high-risk. It is used in children who had at least a partial response to other drugs and other types of treatment.

Contraindications

• a bad infection
• a disorder with excess antidiuretic hormone called syndrome of inappropriate antidiuretic hormone
• hemolytic uremic syndrome, a condition that affects the kidney and the blood
• anemia
• decreased blood platelets
• low levels of a type of white blood cell called neutrophils
• inflammation of the spinal cord
• a painful condition that affects the nerves in the legs and arms called peripheral neuropathy
• low blood pressure
• an inability to completely empty the bladder
• pregnancy
• a patient who is producing milk and breastfeeding
• a type of brain disorder called posterior reversible encephalopathy syndrome

Dosage

Strengths: 17.5 mg/5 mL

Neuroblastoma

17.5 mg/m2/day IV over 10 to 20 hours for 4 consecutive days for a maximum of 5 cycles:

• Infuse on days 4, 5, 6, and 7 during cycles 1, 3, and 5 (cycles 1, 3, and 5 are 24 days in duration).
• Infuse on days 8, 9, 10, and 11 during cycles 2 and 4 (cycles 2 and 4 are 32 days in duration).

Rate of Infusion:

• Initiate at 0.875 mg/m2/hour for 30 minutes. Gradually increase as tolerated to a maximum rate of 1.75 mg/m2/hour.

REQUIRED PRE-TREATMENT AND GUIDELINES FOR PAIN MANAGEMENT IV HYDRATION:
1) Hydration:

• Administer 0.9% sodium chloride 10 mL/kg IV over one hour just prior to initiating each infusion.

2) Analgesics:

• Administer morphine 50 mcg/kg IV immediately prior to infusion and then continue as a morphine drip at an infusion rate of 20 to 50 mcg/kg/hour during and for 2 hours following completion of therapy.
• Administer an additional 25 mcg/kg to 50 mcg/kg IV doses of morphine as needed for pain up to once every 2 hours followed by an increase in the morphine infusion rate in stable patients.
• Consider using fentanyl or hydromorphone if morphine is not tolerated.
• If pain is inadequately managed with opioids, consider use of gabapentin or lidocaine in conjunction with IV morphine.

3) Antihistamines and Antipyretics:

• Administer an antihistamine such as diphenhydramine (0.5 to 1 mg/kg; maximum dose 50 mg) IV over 10 to 15 minutes starting 20 minutes prior to initiation of therapy and as tolerated every 4 to 6 hours during therapy.
• Administer acetaminophen (10 to 15 mg/kg; maximum dose 650 mg) 20 minutes prior to each infusion and every 4 to 6 hours as needed for fever or pain. -Administer ibuprofen (5 to 10 mg/kg) every 6 hours as needed for control of persistent fever or pain.

Dose Adjustments

Permanently discontinue therapy for:

• Grade 3 or 4 anaphylaxis
• Grade 3 or 4 serum sickness
• Grade 3 pain unresponsive to maximum supportive measures
• Grade 4 sensory neuropathy or Grade 3 sensory neuropathy that interferes with daily activities for more than 2 weeks
• Grade 2 or greater peripheral motor neuropathy
• Urinary retention that persists following discontinuation of opioids
• Transverse myelitis
• Reversible posterior leukoencephalopathy syndrome (RPLS)
• Subtotal or total vision loss
• Grade 4 hyponatremia despite appropriate fluid management

Infusion-related reactions:

• Mild to moderate reaction (e.g., transient rash, fever, rigors, and localized urticaria that respond promptly to symptomatic treatment): Reduce infusion rate by 50%; monitor closely. Upon resolution, gradually increase the infusion rate up to a maximum of 1.75 mg/m2/hour.
• Severe or prolonged reaction (e.g., mild bronchospasm without other symptoms, angioedema that does not affect the airway): Interrupt infusion; if symptoms resolve rapidly, resume infusion at 50% of the previous rate and monitor closely. If the reaction recurs, discontinue therapy until the following day. If symptoms resolve and further treatment is warranted, premedicated with IV hydrocortisone 1 mg/kg (maximum 50 mg) and infuse at a rate of 0.875 mg/m2/hour in an intensive care unit. If the reaction recurs a second time, permanently discontinue therapy.

Neurological Disorders of the Eye:

• The onset of reaction: Discontinue the infusion until resolved; upon resolution, reduce the dose by 50%.
• First recurrence or if accompanied by visual impairment: Permanently discontinue therapy.

Capillary leak syndrome:

• Moderate to severe, but not life-threatening: Interrupt infusion; upon resolution, resume infusion at 50% of the previous rate.
• Life-threatening: Discontinue infusion for the current cycle; in subsequent cycles, infuse at 50% of the previous rate. If life-threatening capillary leak syndrome recurs, permanently discontinue therapy.

Hemolytic uremic syndrome:

• Permanently discontinue therapy and administer supportive management.

Hyponatremia, grade 4 (despite appropriate fluid management):

• Permanently discontinue therapy.

Hypotension requiring medical intervention:

• Interrupt infusion; upon resolution, resume infusion at 50% of the previous rate. If blood pressure remains stable for 2 hours or more, increase infusion rate as tolerated up to a maximum rate of 1.75 mg/m2/hour.

Severe systemic infection or sepsis:

• Discontinue therapy until the infection resolves; may resume therapy with subsequent cycles.

Administration advice:

• Verify that patients have adequate hematologic, respiratory, hepatic, and renal function prior to initiating each course of therapy.
• Administer required premedication and hydration prior to initiation of each course of therapy.

Side Effects

The Most Common

• vomiting
• diarrhea
• nausea
• decreased appetite
• weight gain
• fever, chills, and other signs of infection
• blurred vision
• changes in vision
• sensitivity to light
• drooping eyelids
• seizures
• muscle cramps
• rapid heartbeat
• fatigue
• blood in urine
• unusual bleeding or bruising
• vomit that is bloody or looks like coffee grounds
• stool that contains bright red blood or is black and tarry
• pale skin
• swelling of the hands, feet, ankles, or lower legs
• shortness of breath
• fainting, dizziness, or lightheadedness
• sudden vision loss or vision changes;
• headache, confusion, thinking problems, seizures;
• nerve problems–sharp or shooting pain, numbness or tingling, burning or cold feeling, weakness, loss of movement, problems with walking or daily activities, loss of bladder or bowel control;
• low blood cell counts–fever, chills, tiredness, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands, and feet, feeling light-headed or short of breath; or
• signs of an electrolyte imbalance–increased thirst or urination, constipation, muscle pain or weakness, leg cramps, numbness or tingling, feeling jittery, irregular heartbeats, fluttering in your chest, or a choking feeling.

More common

• Black, tarry, stools
• bleeding gums
• blood in the urine or stools
• blurred vision
• chills
• cloudy urine
• coma
• confusion
• convulsions
• cough or hoarseness
• decrease or increase in the amount of urine
• difficult or labored breathing
• dizziness
• dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
• dry mouth
• fainting or lightheadedness
• fast or irregular heartbeat
• fever
• headache
• hives or welts, itching, or skin rash
• increased thirst
• irregular heartbeat
• loss of appetite
• lower back or side pain
• muscle pain or cramps
• nausea or vomiting
• noisy breathing
• numbness or tingling in the hands, feet, or lips
• painful or difficult urination
• pale skin
• pinpoint red spots on the skin
• redness of the skin
• sore throat
• stomach pain
• sweating
• swelling of the face, hands, ankles, feet, or lower legs
• tightness in the chest
• troubled breathing with exertion
• ulcers, sores, or white spots in the mouth
• unusual bleeding or bruising
• unusual tiredness or weakness

Rare

• Back pain
• bigger, dilated, or enlarged pupils (black part of the eye)
• burning, numbness, tingling, or painful sensations
• change in color vision
• change in the ability to see colors, especially blue or yellow
• chest pain
• difficulty seeing at night
• drooping upper eyelids
• increased sensitivity of the eyes to sunlight
• muscle or joint pain
• nerve pain
• pain in the arms or legs
• unsteadiness or awkwardness
• weakness in the arms, hands, legs, or feet
• Yellow eyes or skin

Drug Interaction

DRUG	INTERACTION
Abatacept	The risk or severity of adverse effects can be increased when Abatacept is combined with Dinutuximab.
Abciximab	The risk or severity of bleeding can be increased when Abciximab is combined with Dinutuximab.
Acebutolol	The risk or severity of adverse effects can be increased when Acebutolol is combined with Dinutuximab.
Acenocoumarol	The risk or severity of bleeding can be increased when Acenocoumarol is combined with Dinutuximab.
Acetylsalicylic acid	The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Dinutuximab.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Dinutuximab.
Adenovirus type	The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Dinutuximab.
Aducanumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Aducanumab.
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dinutuximab.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Dinutuximab.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dinutuximab.
Alirocumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Alirocumab.
Aliskiren	The risk or severity of adverse effects can be increased when Aliskiren is combined with Dinutuximab.
Allogeneic	The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Dinutuximab.
Allopurinol	The risk or severity of adverse effects can be increased when Allopurinol is combined with Dinutuximab.
Alteplase	The risk or severity of bleeding can be increased when Alteplase is combined with Dinutuximab.
Altretamine	The risk or severity of adverse effects can be increased when Altretamine is combined with Dinutuximab.
Ambrisentan	Dinutuximab may increase the hypotensive activities of Ambrisentan.
Amifostine	The risk or severity of adverse effects can be increased when Amifostine is combined with Dinutuximab.
Amiloride	The risk or severity of adverse effects can be increased when Amiloride is combined with Dinutuximab.
Amiodarone	The risk or severity of adverse effects can be increased when Amiodarone is combined with Dinutuximab.
Amivantamab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Amivantamab.
Amlodipine	The risk or severity of adverse effects can be increased when Amlodipine is combined with Dinutuximab.
Amobarbital	Amobarbital may increase the hypotensive activities of Dinutuximab.
Amphotericin B	The risk or severity of adverse effects can be increased when Amphotericin B is combined with Dinutuximab.
Amsacrine	The risk or severity of adverse effects can be increased when Amsacrine is combined with Dinutuximab.
Amyl Nitrite	The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Dinutuximab.
Anagrelide	The risk or severity of bleeding can be increased when Anagrelide is combined with Dinutuximab.
Anakinra	The risk or severity of adverse effects can be increased when Anakinra is combined with Dinutuximab.
Ancrod	The risk or severity of bleeding can be increased when Ancrod is combined with Dinutuximab.
Anifrolumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Anifrolumab.
Anistreplase	The risk or severity of bleeding can be increased when Anistreplase is combined with Dinutuximab.
Ansuvimab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Ansuvimab.
Anthrax immune	The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Dinutuximab.
Anthrax vaccine	The risk or severity of infection can be increased when Anthrax vaccine is combined with Dinutuximab.
Antilymphocyte	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Antilymphocyte immunoglobulin (horse).
Antithrombin Alfa	The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Dinutuximab.
Antithrombin III	The risk or severity of bleeding can be increased when Antithrombin III human is combined with Dinutuximab.
Antithymocyte	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dinutuximab.
Apixaban	The risk or severity of bleeding can be increased when Apixaban is combined with Dinutuximab.
Apomorphine	The risk or severity of adverse effects can be increased when Apomorphine is combined with Dinutuximab.
Apremilast	The risk or severity of adverse effects can be increased when Apremilast is combined with Dinutuximab.
Ardeparin	The risk or severity of bleeding can be increased when Ardeparin is combined with Dinutuximab.
Argatroban	The risk or severity of bleeding can be increased when Argatroban is combined with Dinutuximab.
Aripiprazole	Aripiprazole may increase the hypotensive activities of Dinutuximab.
Aripiprazole	Aripiprazole lauroxil may increase the hypotensive activities of Dinutuximab.
Arsenic trioxide	The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Dinutuximab.
Articaine	The risk or severity of methemoglobinemia can be increased when Dinutuximab is combined with Articaine.
Asfotase alfa	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Asfotase alfa.
COVID-19 Vaccine	The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Dinutuximab.
Atenolol	The risk or severity of adverse effects can be increased when Atenolol is combined with Dinutuximab.
Atezolizumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Atezolizumab.
Atoltivimab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Atoltivimab.
Avanafil	The risk or severity of hypotension can be increased when Avanafil is combined with Dinutuximab.
Avelumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Avelumab.
Azacitidine	The risk or severity of adverse effects can be increased when Azacitidine is combined with Dinutuximab.
Azathioprine	The risk or severity of adverse effects can be increased when Azathioprine is combined with Dinutuximab.
Azilsartan	The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Dinutuximab.
Bacillus calmette	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Dinutuximab.
Bacillus antigen	The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Dinutuximab.
Bacillus	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Dinutuximab.
Bamlanivimab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Bamlanivimab.
Baricitinib	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Baricitinib.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Dinutuximab.
BCG vaccine	The risk or severity of infection can be increased when BCG vaccine is combined with Dinutuximab.
Bebtelovimab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Bebtelovimab.
Beclomethasone	The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Dinutuximab.
Belantamab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Belantamab mafodotin.
Belatacept	The risk or severity of adverse effects can be increased when Belatacept is combined with Dinutuximab.
Belimumab	The risk or severity of adverse effects can be increased when Belimumab is combined with Dinutuximab.
Belinostat	The risk or severity of adverse effects can be increased when Belinostat is combined with Dinutuximab.
Belumosudil	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Belumosudil.
Bemiparin	The risk or severity of bleeding can be increased when Bemiparin is combined with Dinutuximab.
Benazepril	The risk or severity of adverse effects can be increased when Benazepril is combined with Dinutuximab.
Bendamustine	The risk or severity of adverse effects can be increased when Bendamustine is combined with Dinutuximab.
Bendroflumethiazide	The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Dinutuximab.
Benralizumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Benralizumab.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Dinutuximab is combined with Benzocaine.
Benzthiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Dinutuximab.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Dinutuximab is combined with Benzyl alcohol.
Bepridil	The risk or severity of adverse effects can be increased when Bepridil is combined with Dinutuximab.
Besilesomab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Besilesomab.
Betamethasone	The risk or severity of adverse effects can be increased when Betamethasone is combined with Dinutuximab.
Betaxolol	The risk or severity of adverse effects can be increased when Betaxolol is combined with Dinutuximab.
Bethanidine	Dinutuximab may increase the hypotensive activities of Bethanidine.
Betrixaban	The risk or severity of bleeding can be increased when Betrixaban is combined with Dinutuximab.
Bevacizumab	The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dinutuximab.
Bexarotene	The risk or severity of adverse effects can be increased when Bexarotene is combined with Dinutuximab.
Bezlotoxumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Bezlotoxumab.
Bimekizumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Bimekizumab.
Bisoprolol	The risk or severity of adverse effects can be increased when Bisoprolol is combined with Dinutuximab.
Bivalirudin	The risk or severity of bleeding can be increased when Bivalirudin is combined with Dinutuximab.
Bleomycin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Dinutuximab.
Blinatumomab	The risk or severity of adverse effects can be increased when Blinatumomab is combined with Dinutuximab.
Bordetella	The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Dinutuximab.
Bortezomib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Dinutuximab.
Bosentan	Dinutuximab may increase the hypotensive activities of Bosentan.
Bosutinib	The risk or severity of adverse effects can be increased when Bosutinib is combined with Dinutuximab.
Brentuximab vedotin	The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Dinutuximab.
Bretylium	The risk or severity of adverse effects can be increased when Bretylium is combined with Dinutuximab.

Brodalumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Brodalumab.
Brolucizumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Brolucizumab.
Bromocriptine	The risk or severity of adverse effects can be increased when Bromocriptine is combined with Dinutuximab.
Budesonide	The risk or severity of adverse effects can be increased when Budesonide is combined with Dinutuximab.
Bumetanide	The risk or severity of adverse effects can be increased when Bumetanide is combined with Dinutuximab.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Dinutuximab is combined with Bupivacaine.
Burosumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Burosumab.
Busulfan	The risk or severity of adverse effects can be increased when Busulfan is combined with Dinutuximab.
Butabarbital	Butabarbital may increase the hypotensive activities of Dinutuximab.
Butacaine	The risk or severity of methemoglobinemia can be increased when Dinutuximab is combined with Butacaine.
Butalbital	Butalbital may increase the hypotensive activities of Dinutuximab.
Butamben	The risk or severity of methemoglobinemia can be increased when Dinutuximab is combined with Butamben.
Cabazitaxel	The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dinutuximab.
Canagliflozin	The risk or severity of adverse effects can be increased when Canagliflozin is combined with Dinutuximab.
Canakinumab	The risk or severity of adverse effects can be increased when Canakinumab is combined with Dinutuximab.
Candesartan cil	The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Dinutuximab.
Cangrelor	The risk or severity of bleeding can be increased when Cangrelor is combined with Dinutuximab.
Capecitabine	The risk or severity of adverse effects can be increased when Capecitabine is combined with Dinutuximab.
Caplacizumab	The risk or severity of bleeding can be increased when Caplacizumab is combined with Dinutuximab.
Capromab pend	The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Dinutuximab.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Dinutuximab is combined with Capsaicin.
Captopril	The risk or severity of adverse effects can be increased when Captopril is combined with Dinutuximab.
Carbamazepine	The risk or severity of adverse effects can be increased when Carbamazepine is combined with Dinutuximab.
Carbetocin	The risk or severity of adverse effects can be increased when Carbetocin is combined with Dinutuximab.
Carboplatin	The risk or severity of adverse effects can be increased when Carboplatin is combined with Dinutuximab.
Carfilzomib	The risk or severity of adverse effects can be increased when Carfilzomib is combined with Dinutuximab.
Carmustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Dinutuximab.
Carvedilol	The risk or severity of adverse effects can be increased when Carvedilol is combined with Dinutuximab.
Casirivimab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Casirivimab.
Catumaxomab	The risk or severity of adverse effects can be increased when Catumaxomab is combined with Dinutuximab.
Celiprolol	Dinutuximab may increase the hypotensive activities of Celiprolol.
Cemiplimab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Cemiplimab.
Certolizumab pegol	The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Dinutuximab.
Cetuximab	The risk or severity of adverse effects can be increased when Cetuximab is combined with Dinutuximab.
Chlorambucil	The risk or severity of adverse effects can be increased when Chlorambucil is combined with Dinutuximab.
Chloramphenicol	The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Dinutuximab.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Dinutuximab is combined with Chloroprocaine.
Chlorothiazide	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Dinutuximab.
Chlorpromazine	The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dinutuximab.
Chlorthalidone	The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Dinutuximab.
Ciclesonide	The risk or severity of adverse effects can be increased when Ciclesonide is combined with Dinutuximab.
Cilazapril	The risk or severity of adverse effects can be increased when Cilazapril is combined with Dinutuximab.
Cilgavimab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Cilgavimab.
Cilostazol	The risk or severity of bleeding can be increased when Cilostazol is combined with Dinutuximab.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Dinutuximab is combined with Cinchocaine.
Cisplatin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Dinutuximab.
Cladribine	The risk or severity of adverse effects can be increased when Cladribine is combined with Dinutuximab.
Clevidipine	The risk or severity of adverse effects can be increased when Clevidipine is combined with Dinutuximab.
Clobetasol propionate	The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Dinutuximab.
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Dinutuximab.
Clomipramine	The risk or severity of adverse effects can be increased when Clomipramine is combined with Dinutuximab.
Clonidine	The risk or severity of adverse effects can be increased when Clonidine is combined with Dinutuximab.
Clopidogrel	The risk or severity of bleeding can be increased when Clopidogrel is combined with Dinutuximab.
Clostridium	The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dinutuximab.
Clozapine	The risk or severity of neutropenia can be increased when Dinutuximab is combined with Clozapine.
Cocaine	The risk or severity of methemoglobinemia can be increased when Dinutuximab is combined with Cocaine.
Conivaptan	The risk or severity of adverse effects can be increased when Conivaptan is combined with Dinutuximab.
Conjugated	Conjugated estrogens may increase the thrombogenic activities of Dinutuximab.
Corticotropin	The risk or severity of adverse effects can be increased when Corticotropin is combined with Dinutuximab.
Cortisone acetate	The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Dinutuximab.
Corynebacterium	The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dinutuximab.
Cryptenamine	Dinutuximab may increase the hypotensive activities of Cryptenamine.
Cyanocobalamin	The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Dinutuximab.
Cyclopenthiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Dinutuximab.
Cyclophosphamide	The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Dinutuximab.
Cyclosporine	Dinutuximab may increase the immunosuppressive activities of Cyclosporine.
Cyclothiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Dinutuximab.
Cytarabine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Dinutuximab.
Dabigatran	The risk or severity of bleeding can be increased when Dabigatran is combined with Dinutuximab.
Dabigatran etexilate	The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Dinutuximab.
Dacarbazine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Dinutuximab.
Dactinomycin	The risk or severity of adverse effects can be increased when Dactinomycin is combined with Dinutuximab.
Dalteparin	The risk or severity of bleeding can be increased when Dalteparin is combined with Dinutuximab.
Danaparoid	The risk or severity of bleeding can be increased when Danaparoid is combined with Dinutuximab.
Dapagliflozin	The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Dinutuximab.
Daratumumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Daratumumab.
Darbepoetin alfa	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dinutuximab.
Dasatinib	The risk or severity of adverse effects can be increased when Dasatinib is combined with Dinutuximab.
Dasiglucagon	Dinutuximab may increase the hypotensive activities of Dasiglucagon.
Daunorubicin	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Dinutuximab.
Debrisoquine	Dinutuximab may increase the hypotensive activities of Debrisoquine.
Decitabine	The risk or severity of adverse effects can be increased when Decitabine is combined with Dinutuximab.
Defibrotide	The risk or severity of bleeding can be increased when Defibrotide is combined with Dinutuximab.
Deflazacort	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Deflazacort.
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Dinutuximab.
Deserpidine	Dinutuximab may increase the hypotensive activities of Deserpidine.
Desflurane	The risk or severity of adverse effects can be increased when Desflurane is combined with Dinutuximab.
Desirudin	The risk or severity of bleeding can be increased when Desirudin is combined with Dinutuximab.
Desoximetasone	The risk or severity of adverse effects can be increased when Desoximetasone is combined with Dinutuximab.
Deucravacitinib	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Deucravacitinib.
Dexamethasone	The risk or severity of adverse effects can be increased when Dexamethasone is combined with Dinutuximab.
Dexmedetomidine	The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dinutuximab.
Dexrazoxane	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dinutuximab.
Dextran	The risk or severity of bleeding can be increased when Dextran is combined with Dinutuximab.
Diazoxide	The risk or severity of adverse effects can be increased when Diazoxide is combined with Dinutuximab.
Diclofenamide	The risk or severity of adverse effects can be increased when Diclofenamide is combined with Dinutuximab.
Dicoumarol	The risk or severity of bleeding can be increased when Dicoumarol is combined with Dinutuximab.
Dienestrol	Dienestrol may increase the thrombogenic activities of Dinutuximab.
Diethylstilbestrol	Diethylstilbestrol may increase the thrombogenic activities of Dinutuximab.
Difluocortolone	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Difluocortolone.

Docetaxel	The risk or severity of adverse effects can be increased when Docetaxel is combined with Dinutuximab.
Dostarlimab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Dostarlimab.
Doxazosin	The risk or severity of adverse effects can be increased when Doxazosin is combined with Dinutuximab.
Doxorubicin	The risk or severity of adverse effects can be increased when Doxorubicin is combined with Dinutuximab.
Drotrecogin alfa	The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Dinutuximab.
Dulaglutide	The risk or severity of adverse effects can be increased when Dulaglutide is combined with Dinutuximab.
Duloxetine	The risk or severity of orthostatic hypotension and syncope can be increased when Dinutuximab is combined with Duloxetine.
Dupilumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Dupilumab.
Durvalumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Durvalumab.
Dyclonine	The risk or severity of methemoglobinemia can be increased when Dinutuximab is combined with Dyclonine.
Ebola Zaire vacci	The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Dinutuximab.
Eculizumab	The risk or severity of adverse effects can be increased when Eculizumab is combined with Dinutuximab.
Edetic acid	The risk or severity of bleeding can be increased when Edetic acid is combined with Dinutuximab.
Edoxaban	The risk or severity of bleeding can be increased when Edoxaban is combined with Dinutuximab.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Dinutuximab.
Eflapegrastim	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Eflapegrastim.
Eftrenonacog alfa	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Eftrenonacog alfa.
Elotuzumab	The risk or severity of adverse effects can be increased when Elotuzumab is combined with Dinutuximab.
Emapalumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Emapalumab.
Emicizumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Emicizumab.
Empagliflozin	The risk or severity of adverse effects can be increased when Empagliflozin is combined with Dinutuximab.
Enalapril	The risk or severity of adverse effects can be increased when Enalapril is combined with Dinutuximab.
Enalaprilat	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Enalaprilat.
Enoxaparin	The risk or severity of bleeding can be increased when Enoxaparin is combined with Dinutuximab.
Epirubicin	The risk or severity of adverse effects can be increased when Epirubicin is combined with Dinutuximab.
Eplerenone	The risk or severity of adverse effects can be increased when Eplerenone is combined with Dinutuximab.
Epoprostenol	The risk or severity of adverse effects can be increased when Epoprostenol is combined with Dinutuximab.
Eprosartan	The risk or severity of adverse effects can be increased when Eprosartan is combined with Dinutuximab.
Eptifibatide	The risk or severity of bleeding can be increased when Eptifibatide is combined with Dinutuximab.
Eptinezumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Eptinezumab.
Erenumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Erenumab.
Eribulin	The risk or severity of adverse effects can be increased when Eribulin is combined with Dinutuximab.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Dinutuximab.
Esmolol	The risk or severity of adverse effects can be increased when Esmolol is combined with Dinutuximab.
Esterified estrogens	Esterified estrogens may increase the thrombogenic activities of Dinutuximab.
Estetrol	Estetrol may increase the thrombogenic activities of Dinutuximab.
Estradiol	Estradiol may increase the thrombogenic activities of Dinutuximab.
Estradiol acetate	Estradiol acetate may increase the thrombogenic activities of Dinutuximab.
Estradiol benzoate	Estradiol benzoate may increase the thrombogenic activities of Dinutuximab.
Estradiol cypionate	Estradiol cypionate may increase the thrombogenic activities of Dinutuximab.
Estradiol valerate	Estradiol valerate may increase the thrombogenic activities of Dinutuximab.
Estramustine	The risk or severity of adverse effects can be increased when Estramustine is combined with Dinutuximab.
Estriol	Estriol may increase the thrombogenic activities of Dinutuximab.
Estrone	Estrone may increase the thrombogenic activities of Dinutuximab.
Estrone sulfate	Estrone sulfate may increase the thrombogenic activities of Dinutuximab.
Etacrynic acid	The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dinutuximab.
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Dinutuximab.
Ethanol	Ethanol may increase the hypotensive activities of Dinutuximab.
Ethinylestradiol	Ethinylestradiol may increase the thrombogenic activities of Dinutuximab.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Dinutuximab is combined with Ethyl chloride.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Dinutuximab is combined with Etidocaine.
Etoposide	The risk or severity of adverse effects can be increased when Etoposide is combined with Dinutuximab.
Everolimus	The risk or severity of adverse effects can be increased when Everolimus is combined with Dinutuximab.
Evolocumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Evolocumab.
Famtozinameran	The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Dinutuximab.
Fanolesomab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Fanolesomab.
Felodipine	The risk or severity of adverse effects can be increased when Felodipine is combined with Dinutuximab.
Fenoldopam	The risk or severity of adverse effects can be increased when Fenoldopam is combined with Dinutuximab.
Filgotinib	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Filgotinib.
Fingolimod	Dinutuximab may increase the immunosuppressive activities of Fingolimod.
Floxuridine	The risk or severity of adverse effects can be increased when Floxuridine is combined with Dinutuximab.
Flucytosine	The risk or severity of adverse effects can be increased when Flucytosine is combined with Dinutuximab.
Fludarabine	The risk or severity of adverse effects can be increased when Fludarabine is combined with Dinutuximab.
Fludrocortisone	The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Dinutuximab.
Fluindione	The risk or severity of bleeding can be increased when Fluindione is combined with Dinutuximab.
Flunisolide	The risk or severity of adverse effects can be increased when Flunisolide is combined with Dinutuximab.
Fluocinolone	The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Dinutuximab.
Fluocinonide	The risk or severity of adverse effects can be increased when Fluocinonide is combined with Dinutuximab.
Fluocortolone	The risk or severity of adverse effects can be increased when Fluocortolone is combined with Dinutuximab.
Fluorometholone	The risk or severity of adverse effects can be increased when Fluorometholone is combined with Dinutuximab.
Fluorouracil	The risk or severity of adverse effects can be increased when Fluorouracil is combined with Dinutuximab.
Flupentixol	The risk or severity of myelosuppression can be increased when Flupentixol is combined with Dinutuximab.
Fluprednisolone	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Fluprednisolone.
Fluticasone	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Fluticasone.
Fluticasone furoate	The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Dinutuximab.
Fluticasone	The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Dinutuximab.
Fondaparinux	The risk or severity of bleeding can be increased when Fondaparinux is combined with Dinutuximab.
Fosinopril	The risk or severity of adverse effects can be increased when Fosinopril is combined with Dinutuximab.
Fostamatinib	The risk or severity of hypotension can be increased when Fostamatinib is combined with Dinutuximab.
Fremanezumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Fremanezumab.
Furosemide	The risk or severity of adverse effects can be increased when Furosemide is combined with Dinutuximab.
Galcanezumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Galcanezumab.
Gallium nitrate	The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Dinutuximab.
Gemcitabine	The risk or severity of adverse effects can be increased when Gemcitabine is combined with Dinutuximab.
Gemtuzumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dinutuximab.
Glatiramer	The risk or severity of adverse effects can be increased when Glatiramer is combined with Dinutuximab.
Golimumab	The risk or severity of adverse effects can be increased when Golimumab is combined with Dinutuximab.
Guanabenz	Dinutuximab may increase the hypotensive activities of Guanabenz.
Guanadrel	Dinutuximab may increase the hypotensive activities of Guanadrel.
Guanethidine	Dinutuximab may increase the hypotensive activities of Guanethidine.
Guanfacine	The risk or severity of adverse effects can be increased when Guanfacine is combined with Dinutuximab.
Guanoxan	Dinutuximab may increase the hypotensive activities of Guanoxan.
Guselkumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Guselkumab.

Hydrocortisone	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Hydrocortisone succinate.
Hydroflumethiazide	The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Dinutuximab.
Hydroxychloroquine	The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Dinutuximab.
Hydroxyurea	The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Dinutuximab.
Ibalizumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Ibalizumab.
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dinutuximab.
Ibrutinib	The risk or severity of adverse effects can be increased when Ibrutinib is combined with Dinutuximab.
Icosapent ethyl	The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Dinutuximab.
Idarubicin	The risk or severity of adverse effects can be increased when Idarubicin is combined with Dinutuximab.
Idarucizumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Idarucizumab.
Idelalisib	The risk or severity of adverse effects can be increased when Idelalisib is combined with Dinutuximab.
Ifosfamide	The risk or severity of adverse effects can be increased when Ifosfamide is combined with Dinutuximab.
Iloprost	The risk or severity of adverse effects can be increased when Iloprost is combined with Dinutuximab.
Imatinib	The risk or severity of adverse effects can be increased when Imatinib is combined with Dinutuximab.
Imdevimab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Imdevimab.
Imipramine	The risk or severity of adverse effects can be increased when Imipramine is combined with Dinutuximab.
Imlifidase	The therapeutic efficacy of Dinutuximab can be decreased when used in combination with Imlifidase.
Indapamide	The risk or severity of adverse effects can be increased when Indapamide is combined with Dinutuximab.
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Dinutuximab.
Indoramin	The risk or severity of adverse effects can be increased when Indoramin is combined with Dinutuximab.
Inebilizumab	The risk or severity of infection can be increased when Dinutuximab is combined with Inebilizumab.
Infliximab	The risk or severity of adverse effects can be increased when Infliximab is combined with Dinutuximab.

Labetalol	The risk or severity of adverse effects can be increased when Labetalol is combined with Dinutuximab.
Lacidipine	Dinutuximab may increase the hypotensive activities of Lacidipine.
Lanadelumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Lanadelumab.
Leflunomide	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Leflunomide.
Lenalidomide	The risk or severity of adverse effects can be increased when Lenalidomide is combined with Dinutuximab.
Lepirudin	The risk or severity of bleeding can be increased when Lepirudin is combined with Dinutuximab.
Lercanidipine	The risk or severity of adverse effects can be increased when Lercanidipine is combined with Dinutuximab.
Levamlodipine	Dinutuximab may increase the hypotensive activities of Levamlodipine.
Levobupivacaine	The risk or severity of methemoglobinemia can be increased when Dinutuximab is combined with Levobupivacaine.
Levodopa	The risk or severity of hypotension and orthostatic hypotension can be increased when Dinutuximab is combined with Levodopa.
Levosimendan	The risk or severity of adverse effects can be increased when Levosimendan is combined with Dinutuximab.
Lidocaine	The risk or severity of methemoglobinemia can be increased when Dinutuximab is combined with Lidocaine.
Linezolid	The risk or severity of adverse effects can be increased when Linezolid is combined with Dinutuximab.
Lipegfilgrastim	Dinutuximab may increase the myelosuppressive activities of Lipegfilgrastim.
Lisinopril	The risk or severity of adverse effects can be increased when Lisinopril is combined with Dinutuximab.
Lofexidine	The risk or severity of adverse effects can be increased when Lofexidine is combined with Dinutuximab.
Lomustine	The risk or severity of adverse effects can be increased when Lomustine is combined with Dinutuximab.
Loncastuximab tesirine	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Loncastuximab tesirine.
Lopinavir	The serum concentration of Dinutuximab can be increased when it is combined with Lopinavir.
Losartan	The risk or severity of adverse effects can be increased when Losartan is combined with Dinutuximab.
Macitentan	Dinutuximab may increase the hypotensive activities of Macitentan.
Maftivimab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Maftivimab.
Magnesium	The serum concentration of Magnesium can be decreased when it is combined with Dinutuximab.
Manidipine	Dinutuximab may increase the hypotensive activities of Manidipine.
Mannitol	The risk or severity of adverse effects can be increased when Mannitol is combined with Dinutuximab.
Margetuximab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Margetuximab.
Measles	The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Dinutuximab.
Mecamylamine	The risk or severity of adverse effects can be increased when Mecamylamine is combined with Dinutuximab.

Mepivacaine	The risk or severity of methemoglobinemia can be increased when Dinutuximab is combined with Mepivacaine.
Mepolizumab	The risk or severity of adverse effects can be increased when Mepolizumab is combined with Dinutuximab.
Meprednisone	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Meprednisone.
Mercaptopurine	The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Dinutuximab.
Mestranol	Mestranol may increase the thrombogenic activities of Dinutuximab.
Methazolamide	The risk or severity of adverse effects can be increased when Methazolamide is combined with Dinutuximab.
Methimazole	The risk or severity of adverse effects can be increased when Methimazole is combined with Dinutuximab.
Methohexital	Methohexital may increase the hypotensive activities of Dinutuximab.
Methotrexate	The risk or severity of adverse effects can be increased when Methotrexate is combined with Dinutuximab.
Methoxy	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dinutuximab.
Methyldopa	The risk or severity of adverse effects can be increased when Methyldopa is combined with Dinutuximab.
Methylene blue	Methylene blue may increase the orthostatic hypotensive activities of Dinutuximab.
Methylphenobarbital	Methylphenobarbital may increase the hypotensive activities of Dinutuximab.
Methylprednisolone	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Dinutuximab.
Metolazone	The risk or severity of adverse effects can be increased when Metolazone is combined with Dinutuximab.
Metoprolol	The risk or severity of adverse effects can be increased when Metoprolol is combined with Dinutuximab.
Metyrosine	Dinutuximab may increase the hypotensive activities of Metyrosine.
Minaprine	Minaprine may increase the orthostatic hypotensive activities of Dinutuximab.
Minoxidil	The risk or severity of adverse effects can be increased when Minoxidil is combined with Dinutuximab.
Mirvetuximab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Mirvetuximab Soravtansine.
Mitomycin	The risk or severity of adverse effects can be increased when Mitomycin is combined with Dinutuximab.
Mitoxantrone	The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Dinutuximab.
Moclobemide	Moclobemide may increase the orthostatic hypotensive activities of Dinutuximab.
COVID-19 Vaccine	The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Dinutuximab.
Modified vaccinia	The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Dinutuximab.
Moexipril	The risk or severity of adverse effects can be increased when Moexipril is combined with Dinutuximab.
Mogamulizumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Mogamulizumab.
Mometasone furoate	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Mometasone furoate.
Monomethyl f	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Monomethyl fumarate.
Morphine	The risk or severity of adverse effects can be increased when Morphine is combined with Dinutuximab.
Mosunetuzumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Mosunetuzumab.
Moxonidine	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Moxonidine.
Mumps virus	The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Dinutuximab.
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Dinutuximab.
Muzolimine	Dinutuximab may increase the hypotensive activities of Muzolimine.
Mycophenolate	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Dinutuximab.
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Dinutuximab.
Nabilone	The risk or severity of adverse effects can be increased when Nabilone is combined with Dinutuximab.
Nadolol	The risk or severity of adverse effects can be increased when Nadolol is combined with Dinutuximab.
Nadroparin	The risk or severity of bleeding can be increased when Nadroparin is combined with Dinutuximab.
Natalizumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Natalizumab.
Nebivolol	The risk or severity of adverse effects can be increased when Nebivolol is combined with Dinutuximab.
Necitumumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Necitumumab.
Nelarabine	The risk or severity of adverse effects can be increased when Nelarabine is combined with Dinutuximab.
Nesiritide	The risk or severity of adverse effects can be increased when Nesiritide is combined with Dinutuximab.
Nialamide	Nialamide may increase the orthostatic hypotensive activities of Dinutuximab.
Nicardipine	The risk or severity of adverse effects can be increased when Nicardipine is combined with Dinutuximab.
Nicorandil	Nicorandil may increase the hypotensive activities of Dinutuximab.
Nifedipine	The risk or severity of adverse effects can be increased when Nifedipine is combined with Dinutuximab.
Nilotinib	The risk or severity of adverse effects can be increased when Nilotinib is combined with Dinutuximab.
Nilvadipine	The risk or severity of adverse effects can be increased when Nilvadipine is combined with Dinutuximab.
Nimesulide	The risk or severity of bleeding can be increased when Nimesulide is combined with Dinutuximab.
Nimodipine	The risk or severity of adverse effects can be increased when Nimodipine is combined with Dinutuximab.
Nisoldipine	The risk or severity of adverse effects can be increased when Nisoldipine is combined with Dinutuximab.
Nitrendipine	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Dinutuximab.
Nitric Oxide	The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Dinutuximab.
Nitroglycerin	The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Dinutuximab.
Nitroprusside	The risk or severity of adverse effects can be increased when Nitroprusside is combined with Dinutuximab.
Nitrous acid	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Nitrous acid.
Nivolumab	The risk or severity of adverse effects can be increased when Nivolumab is combined with Dinutuximab.
Nuvaxovid	The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Dinutuximab.
Obiltoxaximab	The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Dinutuximab.
Obinutuzumab	The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Dinutuximab.
Ocrelizumab	Ocrelizumab may increase the immunosuppressive activities of Dinutuximab.
Odesivimab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Odesivimab.
Ofatumumab	The risk or severity of adverse effects can be increased when Ofatumumab is combined with Dinutuximab.
Olanzapine	The risk or severity of adverse effects can be increased when Olanzapine is combined with Dinutuximab.
Olaparib	The risk or severity of adverse effects can be increased when Olaparib is combined with Dinutuximab.
Olaratumab	The risk or severity of adverse effects can be increased when Olaratumab is combined with Dinutuximab.
Olmesartan	The risk or severity of adverse effects can be increased when Olmesartan is combined with Dinutuximab.
Omalizumab	The risk or severity of adverse effects can be increased when Omalizumab is combined with Dinutuximab.
Opicapone	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Opicapone.
Oxaliplatin	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Dinutuximab.
Oxetacaine	The risk or severity of methemoglobinemia can be increased when Dinutuximab is combined with Oxetacaine.
Oxprenolol	The risk or severity of adverse effects can be increased when Oxprenolol is combined with Dinutuximab.
Oxybuprocaine	The risk or severity of methemoglobinemia can be increased when Dinutuximab is combined with Oxybuprocaine.
Ozanimod	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Ozanimod.
Paclitaxel	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Dinutuximab.
Palbociclib	The risk or severity of adverse effects can be increased when Palbociclib is combined with Dinutuximab.
Palifermin	The therapeutic efficacy of Palifermin can be decreased when used in combination with Dinutuximab.
Palivizumab	The risk or severity of adverse effects can be increased when Palivizumab is combined with Dinutuximab.
Panitumumab	The risk or severity of adverse effects can be increased when Panitumumab is combined with Dinutuximab.
Panobinostat	The risk or severity of adverse effects can be increased when Panobinostat is combined with Dinutuximab.
Papaverine	The risk or severity of adverse effects can be increased when Papaverine is combined with Dinutuximab.
Pargyline	Pargyline may increase the orthostatic hypotensive activities of Dinutuximab.
Parnaparin	The risk or severity of bleeding can be increased when Parnaparin is combined with Dinutuximab.
Pazopanib	The risk or severity of adverse effects can be increased when Pazopanib is combined with Dinutuximab.
Pegaspargase	The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dinutuximab.
Pegcetacoplan	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Pegcetacoplan.
Peginesatide	The risk or severity of Thrombosis can be increased when Peginesatide is combined with Dinutuximab.
Peginterferon alfa-2a	The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dinutuximab.
Peginterferon alfa-	The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Dinutuximab.
Peginterferon beta	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Peginterferon beta-1a.
Pembrolizumab	The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Dinutuximab.
Pemetrexed	The risk or severity of adverse effects can be increased when Pemetrexed is combined with Dinutuximab.
Penbutolol	The risk or severity of adverse effects can be increased when Penbutolol is combined with Dinutuximab.

Penicillamine	The risk or severity of adverse effects can be increased when Penicillamine is combined with Dinutuximab.
Pentobarbital	Pentobarbital may increase the hypotensive activities of Dinutuximab.
Pentolinium	Dinutuximab may increase the hypotensive activities of Pentolinium.
Pentosan	The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Dinutuximab.
Pentostatin	The risk or severity of adverse effects can be increased when Pentostatin is combined with Dinutuximab.
Pentoxifylline	The risk or severity of bleeding can be increased when Pentoxifylline is combined with Dinutuximab.
Perindopril	The risk or severity of adverse effects can be increased when Perindopril is combined with Dinutuximab.
Pertussis vaccine	The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Dinutuximab.
Pertuzumab	The risk or severity of adverse effects can be increased when Pertuzumab is combined with Dinutuximab.
Phenelzine	Phenelzine may increase the orthostatic hypotensive activities of Dinutuximab.
Phenindione	The risk or severity of bleeding can be increased when Phenindione is combined with Dinutuximab.
Phenobarbital	Phenobarbital may increase the hypotensive activities of Dinutuximab.
Phenol	The risk or severity of methemoglobinemia can be increased when Dinutuximab is combined with Phenol.
Phenoxybenzamine	The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Dinutuximab.
Phenprocoumon	The risk or severity of bleeding can be increased when Phenprocoumon is combined with Dinutuximab.
Phentolamine	The risk or severity of adverse effects can be increased when Phentolamine is combined with Dinutuximab.
Phenylalanine	The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dinutuximab.
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dinutuximab.
Pinacidil	Dinutuximab may increase the hypotensive activities of Pinacidil.
Pindolol	The risk or severity of adverse effects can be increased when Pindolol is combined with Dinutuximab.
Pirfenidone	The risk or severity of adverse effects can be increased when Pirfenidone is combined with Dinutuximab.
Polatuzumab vedotin	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Polatuzumab vedotin.
Polyestradiol	Polyestradiol phosphate may increase the thrombogenic activities of Dinutuximab.
Polythiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Dinutuximab.
Pomalidomide	The risk or severity of adverse effects can be increased when Pomalidomide is combined with Dinutuximab.
Ponatinib	The risk or severity of adverse effects can be increased when Ponatinib is combined with Dinutuximab.
Ponesimod	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Ponesimod.
Practolol	Dinutuximab may increase the hypotensive activities of Practolol.
Pralatrexate	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Dinutuximab.
Pramipexole	The risk or severity of adverse effects can be increased when Pramipexole is combined with Dinutuximab.
Pramocaine	The risk or severity of methemoglobinemia can be increased when Dinutuximab is combined with Pramocaine.
Prasugrel	The risk or severity of bleeding can be increased when Prasugrel is combined with Dinutuximab.
Prazosin	The risk or severity of adverse effects can be increased when Prazosin is combined with Dinutuximab.
Prednisolone	The risk or severity of adverse effects can be increased when Prednisolone is combined with Dinutuximab.
Prednisone	The risk or severity of adverse effects can be increased when Prednisone is combined with Dinutuximab.
Prilocaine	The risk or severity of methemoglobinemia can be increased when Dinutuximab is combined with Prilocaine.
Primidone	Primidone may increase the hypotensive activities of Dinutuximab.
Procaine	The risk or severity of methemoglobinemia can be increased when Dinutuximab is combined with Procaine.
Procarbazine	The risk or severity of adverse effects can be increased when Procarbazine is combined with Dinutuximab.
Proparacaine	The risk or severity of methemoglobinemia can be increased when Dinutuximab is combined with Proparacaine.
Propofol	The risk or severity of adverse effects can be increased when Propofol is combined with Dinutuximab.
Propoxycaine	The risk or severity of methemoglobinemia can be increased when Dinutuximab is combined with Propoxycaine.
Propranolol	The risk or severity of adverse effects can be increased when Propranolol is combined with Dinutuximab.
Propylthiouracil	The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Dinutuximab.
Protein C	The risk or severity of bleeding can be increased when Protein C is combined with Dinutuximab.
Protein S human	The risk or severity of bleeding can be increased when Protein S human is combined with Dinutuximab.
Quetiapine	The risk or severity of adverse effects can be increased when Quetiapine is combined with Dinutuximab.
Quinapril	The risk or severity of adverse effects can be increased when Quinapril is combined with Dinutuximab.
Quinestrol	Quinestrol may increase the thrombogenic activities of Dinutuximab.
Rabies immune	The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Dinutuximab.
Rabies antigen, A	The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Dinutuximab.
Rabies antigen, B	The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Dinutuximab.
Raltitrexed	The risk or severity of adverse effects can be increased when Raltitrexed is combined with Dinutuximab.
Ramipril	The risk or severity of adverse effects can be increased when Ramipril is combined with Dinutuximab.
Ramucirumab	The risk or severity of adverse effects can be increased when Ramucirumab is combined with Dinutuximab.
Ranibizumab	The risk or severity of adverse effects can be increased when Ranibizumab is combined with Dinutuximab.
Rasagiline	Rasagiline may increase the orthostatic hypotensive activities of Dinutuximab.
Ravulizumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Ravulizumab.
Raxibacumab	The risk or severity of adverse effects can be increased when Raxibacumab is combined with Dinutuximab.
Remifentanil	The risk or severity of adverse effects can be increased when Remifentanil is combined with Dinutuximab.
Rescinnamine	Dinutuximab may increase the hypotensive activities of Rescinnamine.
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Dinutuximab.
Reslizumab	The risk or severity of adverse effects can be increased when Reslizumab is combined with Dinutuximab.
Reteplase	The risk or severity of bleeding can be increased when Reteplase is combined with Dinutuximab.
Reviparin	The risk or severity of bleeding can be increased when Reviparin is combined with Dinutuximab.
Rilmenidine	Dinutuximab may increase the hypotensive activities of Rilmenidine.
Rilonacept	The risk or severity of adverse effects can be increased when Rilonacept is combined with Dinutuximab.
Riociguat	The risk or severity of adverse effects can be increased when Riociguat is combined with Dinutuximab.
Risankizumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Risankizumab.
Risperidone	Dinutuximab may increase the hypotensive activities of Risperidone.
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Dinutuximab.
Rivaroxaban	The risk or severity of bleeding can be increased when Rivaroxaban is combined with Dinutuximab.
Roflumilast	Roflumilast may increase the immunosuppressive activities of Dinutuximab.
Romosozumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Romosozumab.
Ropeginterferon	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Ropeginterferon alfa-2b.
Ropinirole	The risk or severity of adverse effects can be increased when Ropinirole is combined with Dinutuximab.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Dinutuximab is combined with Ropivacaine.
Rotavirus vaccine	The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Dinutuximab.
Rotigotine	The risk or severity of adverse effects can be increased when Rotigotine is combined with Dinutuximab.
Rubella virus	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Dinutuximab.
Ruxolitinib	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Dinutuximab.
Sacituzumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Sacituzumab govitecan.
Sacubitril	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Sacubitril.
Safinamide	Safinamide may increase the orthostatic hypotensive activities of Dinutuximab.
Sarilumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Sarilumab.
Satralizumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Satralizumab.
Secobarbital	Secobarbital may increase the hypotensive activities of Dinutuximab.
Secukinumab	The risk or severity of adverse effects can be increased when Secukinumab is combined with Dinutuximab.
Selegiline	Selegiline may increase the orthostatic hypotensive activities of Dinutuximab.
Selexipag	Dinutuximab may increase the hypotensive activities of Selexipag.
Sevoflurane	The risk or severity of adverse effects can be increased when Sevoflurane is combined with Dinutuximab.
Sildenafil	The risk or severity of hypotension can be increased when Sildenafil is combined with Dinutuximab.
Siltuximab	The risk or severity of adverse effects can be increased when Siltuximab is combined with Dinutuximab.
Siponimod	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Siponimod.
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dinutuximab.
Sirolimus	The risk or severity of adverse effects can be increased when Sirolimus is combined with Dinutuximab.
Sitaxentan	Dinutuximab may increase the hypotensive activities of Sitaxentan.
Smallpox	The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Dinutuximab.
Sodium citrate	The risk or severity of bleeding can be increased when Sodium citrate is combined with Dinutuximab.

Sorafenib	The risk or severity of adverse effects can be increased when Sorafenib is combined with Dinutuximab.
Sotalol	The risk or severity of adverse effects can be increased when Sotalol is combined with Dinutuximab.
Sotrovimab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Sotrovimab.
Spesolimab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Spesolimab.
Spirapril	Dinutuximab may increase the hypotensive activities of Spirapril.
Spironolactone	The risk or severity of adverse effects can be increased when Spironolactone is combined with Dinutuximab.
Streptokinase	The risk or severity of adverse effects can be increased when Streptokinase is combined with Dinutuximab.
Streptozocin	The risk or severity of adverse effects can be increased when Streptozocin is combined with Dinutuximab.
Sufentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Dinutuximab.
Sulesomab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Sulesomab.
Sulfamethoxazole	The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Dinutuximab.
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Dinutuximab.
Sulfinpyrazone	The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Dinutuximab.
Sulodexide	The risk or severity of bleeding can be increased when Sulodexide is combined with Dinutuximab.
Sunitinib	The risk or severity of adverse effects can be increased when Sunitinib is combined with Dinutuximab.
Sutimlimab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Sutimlimab.
S Estrogens, A	Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Dinutuximab.
SEstrogens, B	Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Dinutuximab.
Tacrolimus	Tacrolimus may increase the immunosuppressive activities of Dinutuximab.
Tadalafil	Dinutuximab may increase the hypotensive activities of Tadalafil.
Tafasitamab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Tafasitamab.
Tamsulosin	The risk or severity of adverse effects can be increased when Tamsulosin is combined with Dinutuximab.
Tedizolid phosphate	The risk or severity of myelosuppression can be increased when Tedizolid phosphate is combined with Dinutuximab.
Telmisartan	The risk or severity of adverse effects can be increased when Telmisartan is combined with Dinutuximab.
Temozolomide	The risk or severity of adverse effects can be increased when Temozolomide is combined with Dinutuximab.
Temsirolimus	The risk or severity of adverse effects can be increased when Temsirolimus is combined with Dinutuximab.
Tenecteplase	The risk or severity of bleeding can be increased when Tenecteplase is combined with Dinutuximab.
Teniposide	The risk or severity of adverse effects can be increased when Teniposide is combined with Dinutuximab.
Teplizumab	The risk or severity of adverse effects can be increased when Teplizumab is combined with Dinutuximab.
Teprotumumab	The risk or severity of adverse effects can be increased when Teprotumumab is combined with Dinutuximab.
Terazosin	The risk or severity of adverse effects can be increased when Terazosin is combined with Dinutuximab.
Teriflunomide	The risk or severity of adverse effects can be increased when Teriflunomide is combined with Dinutuximab.
Tetanus immune	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Tetanus immune globulin, human.
Tetracaine	The risk or severity of methemoglobinemia can be increased when Dinutuximab is combined with Tetracaine.
Tezepelumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Tezepelumab.
Thalidomide	The risk or severity of adverse effects can be increased when Thalidomide is combined with Dinutuximab.
Thiamylal	Thiamylal may increase the hypotensive activities of Dinutuximab.
Thiopental	Thiopental may increase the hypotensive activities of Dinutuximab.
Thioridazine	The risk or severity of adverse effects can be increased when Thioridazine is combined with Dinutuximab.
Thiotepa	The risk or severity of adverse effects can be increased when Thiotepa is combined with Dinutuximab.
Tibolone	Tibolone may increase the thrombogenic activities of Dinutuximab.
Ticagrelor	The risk or severity of bleeding can be increased when Ticagrelor is combined with Dinutuximab.
Tick encephalitis	The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Dinutuximab.
Ticlopidine	The risk or severity of bleeding can be increased when Ticlopidine is combined with Dinutuximab.
Tildrakizumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Tildrakizumab.
Timolol	The risk or severity of adverse effects can be increased when Timolol is combined with Dinutuximab.
Tinzaparin	The risk or severity of bleeding can be increased when Tinzaparin is combined with Dinutuximab.
Tioguanine	The risk or severity of adverse effects can be increased when Tioguanine is combined with Dinutuximab.
Tirofiban	The risk or severity of bleeding can be increased when Tirofiban is combined with Dinutuximab.
Tisotumab vedotin	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Tisotumab vedotin.
Tixagevimab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Tixagevimab.
Tixocortol	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Tixocortol.
Tizanidine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Dinutuximab.
Tocilizumab	The risk or severity of adverse effects can be increased when Tocilizumab is combined with Dinutuximab.
Tofacitinib	Dinutuximab may increase the immunosuppressive activities of Tofacitinib.
Tolazoline	The risk or severity of adverse effects can be increased when Tolazoline is combined with Dinutuximab.
Tolcapone	The risk or severity of adverse effects can be increased when Tolcapone is combined with Dinutuximab.
Topotecan	The risk or severity of adverse effects can be increased when Topotecan is combined with Dinutuximab.
Torasemide	The risk or severity of adverse effects can be increased when Torasemide is combined with Dinutuximab.
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Dinutuximab.
Trabectedin	The risk or severity of adverse effects can be increased when Trabectedin is combined with Dinutuximab.
Tralokinumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Tralokinumab.
Trandolapril	The risk or severity of adverse effects can be increased when Trandolapril is combined with Dinutuximab.
Tranylcypromine	Tranylcypromine may increase the orthostatic hypotensive activities of Dinutuximab.
Trastuzumab	Trastuzumab may increase the neutropenic activities of Dinutuximab.
Trastuzumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Trastuzumab deruxtecan.
Trastuzumab	The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Dinutuximab.
Tremelimumab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Tremelimumab.
Treprostinil	Dinutuximab may increase the hypotensive activities of Treprostinil.
Tretinoin	The risk or severity of adverse effects can be increased when Tretinoin is combined with Dinutuximab.
Triamcinolone	The risk or severity of adverse effects can be increased when Triamcinolone is combined with Dinutuximab.
Triamterene	The risk or severity of adverse effects can be increased when Triamterene is combined with Dinutuximab.
Trichlormethiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Dinutuximab.
Trifluridine	The risk or severity of adverse effects can be increased when Trifluridine is combined with Dinutuximab.
Triflusal	The risk or severity of bleeding can be increased when Triflusal is combined with Dinutuximab.
Trilostane	The risk or severity of adverse effects can be increased when Trilostane is combined with Dinutuximab.
Trimethaphan	Dinutuximab may increase the hypotensive activities of Trimethaphan.
Typhoid vaccine	The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Dinutuximab.
Typhoid Vaccine Live	The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Dinutuximab.
Typhoid Vi	The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Dinutuximab.
Udenafil	The risk or severity of hypotension can be increased when Udenafil is combined with Dinutuximab.
Upadacitinib	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Upadacitinib.
Urokinase	The risk or severity of bleeding can be increased when Urokinase is combined with Dinutuximab.
Ustekinumab	The risk or severity of adverse effects can be increased when Ustekinumab is combined with Dinutuximab.
Valsartan	The risk or severity of adverse effects can be increased when Valsartan is combined with Dinutuximab.
Vardenafil	The risk or severity of hypotension can be increased when Vardenafil is combined with Dinutuximab.
Varicella zoster	The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Dinutuximab.
Varicella zoster	The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Dinutuximab.
Vedolizumab	The risk or severity of adverse effects can be increased when Vedolizumab is combined with Dinutuximab.
Verapamil	The risk or severity of adverse effects can be increased when Verapamil is combined with Dinutuximab.
Vericiguat	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Vericiguat.
Vibrio cholerae	The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Dinutuximab.
Vilanterol	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Vilanterol.
Vinblastine	The risk or severity of adverse effects can be increased when Vinblastine is combined with Dinutuximab.
Vincristine	The risk or severity of adverse effects can be increased when Vincristine is combined with Dinutuximab.
Vindesine	The risk or severity of adverse effects can be increased when Vindesine is combined with Dinutuximab.
Vinorelbine	The risk or severity of adverse effects can be increased when Vinorelbine is combined with Dinutuximab.
Voclosporin	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Voclosporin.
Vorapaxar	The risk or severity of bleeding can be increased when Vorapaxar is combined with Dinutuximab.
Vorinostat	The risk or severity of adverse effects can be increased when Vorinostat is combined with Dinutuximab.

Pregnancy and Lactation

US FDA pregnancy category: Not assigned.

Pregnancy

Use is not recommended. Monoclonal antibodies are transported across the placenta in a linear fashion as pregnancy progresses, with the largest amount transferred during the third trimester. Pregnant women should be advised of the potential risk to a fetus. This drug may cause fetal harm based on its mechanism of action. Females of reproductive potential should be advised to use effective contraception during treatment and for two months after the last dose of this drug.

Lactation

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

How should this medicine be used?

Dinutuximab injection comes as a solution (liquid) to be injected intravenously (into a vein) over 10 to 20 hours by a doctor or nurse in a medical facility or infusion center. It is usually given for 4 consecutive days within a treatment cycle for up to 5 cycles.

Be sure to tell the doctor how your child is feeling during the treatment. Your child’s doctor may decrease the dose, or stop the treatment for a while or permanently if your child experiences side effects to the medication.

What special precautions should I follow?

Before receiving dinutuximab injection,

• tell your doctor and pharmacist if your child is allergic to dinutuximab, any other medications, or any of the ingredients in dinutuximab injection. Ask your pharmacist for a list of the ingredients.
• tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products your child is taking or plans to take. Your doctor may need to change the doses of medications or monitor your child carefully for side effects.
• tell your doctor if it is possible that your child could become pregnant. Dinutuximab injection may harm the fetus. If needed, your child should use birth control to prevent pregnancy during treatment with dinutuximab and for up to 2 months after treatment. Talk to your doctor about types of birth control that will work. If your child becomes pregnant while using dinutuximab injection, call your doctor.

References

Show More